# Ruan et al. 2025 - Low-dose Rapamycin for ME/CFS

## Citation
Ruan BT, Bulbule S, Gile B, Reyes A, Chheda B, Bateman L, Bell J, Yellman B, Grach SL, Berner J, Peterson DL, Kaufman D, Roy A, Gottschalk CG. Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy: a pilot study. *Journal of Translational Medicine*. 2025 Oct 21;23:1003.

- **DOI:** 10.1186/s12967-025-07213-8
- **PMID:** 41121328
- **BibTeX key:** `Ruan2025rapamycin`

## Key Findings

### Primary Results
- **74.3% of patients showed recovery** in fatigue, PEM, and orthostatic intolerance
- **PEM improvement:** Mean reduction of 3.34 points (95% CI: 2.31-4.37)
- **Fatigue improvement:** Mean reduction of 1.34 points (95% CI: 0.55-2.14)
- **Orthostatic intolerance:** Mean reduction of 1.79 points (95% CI: 0.95-2.63)
- **Bell Activity Scale:** 14.99% improvement from baseline to day 90

### Mechanism - Autophagy Restoration
- **BECLIN-1 upregulation:** 1.4- to 1.5-fold increase (autophagy marker)
- **pSer258-ATG13 suppression:** >2-fold reduction by day 90 (mTOR-phosphorylated target)
- **Mechanistic correlation:** Biomarker improvement paralleled PEM symptom reduction

### Study Design
- **Type:** Decentralized, uncontrolled observational trial
- **Sample Size:** 86 initiated therapy; 70 completed day 36; 40 completed full 90-day protocol
- **Intervention:** Low-dose rapamycin 6 mg/week
- **Sites:** 6 clinical centers across the U.S., including Dr. Kaufman's Center for Complex Diseases

### Safety
- No serious adverse events
- Most common side effects: transient GI symptoms, headache, insomnia

## Significance
- **First mechanistic treatment trial** linking autophagy dysfunction to PEM
- Provides quantitative evidence for mTOR dysregulation in ME/CFS pathophysiology
- Expert authorship (Bateman, Peterson, Kaufman) lends clinical credibility

## Certainty Assessment
- **Quality:** Medium-High (pilot study in reputable journal, expert authorship)
- **Limitation:** Uncontrolled trial, no placebo arm
- **Status:** Needs RCT replication, but mechanistic findings are robust

## Integration Points
- Chapter on Treatments (pharmacological interventions)
- Chapter on PEM (mechanism and potential treatment)
- Chapter on Pathophysiology (autophagy/mTOR dysfunction)